This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
AMERICAN SHARED HOSPITAL SERVICES (AMEX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement from Mevion Medical Systems, Inc., formerly Still River Systems, Inc., regarding progress in the development of Mevion's compact proton therapy system. AMS owns preferred stock in Mevion and is developing proton therapy centers in Boston (Tufts Medical Center), Orlando (Orlando Regional Healthcare) and Long Beach, California (Long Beach Memorial Medical Center) which are expected to employ the MEVION S250 proton therapy device:
Mevion Medical Systems Delivers the World's First SuperconductingSynchrocyclotron for Proton Therapy to Barnes Jewish Hospital
Delivery Marks a Technical Triumph and the First Stepin Providing Accessible Proton Therapy SolutionsLittleton, MA - October 31st 2011 -
Mevion Medical Systems announced today it has delivered the world's first superconducting synchrocyclotron to the S. Lee Kling Center for Proton Therapy at the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine in St. Louis MO. This inaugural shipment marks the last phase of the manufacturing of the first MEVION S250 proton accelerator module and the first of many to come deliveries of this revolutionary cancer therapy device.
The synchrocyclotron was delivered after a 1,200 mile, 4-day trip from Mevion's Headquarters in Littleton MA to St. Louis MO. "It was a very rewarding day to see our first system leave our factory knowing that what we have achieved may affect and improve the lives of cancer patients," stated Joseph K. Jachinowski, chief executive officer of Mevion Medical Systems. "The innovative design of the MEVION S250 makes adding proton therapy remarkably easier for our hospital partners than what was previously available."
Powered by a TriNiobium Core
TM, the high-energy proton source of the MEVION S250 will preserve all of the treatment benefits of conventional proton treatment systems while removing the obstacles of size, cost and complexity that have limited the wide adoption of this promising cancer treatment modality. The MEVION S250 Proton Therapy System combines a patented, gantry-mounted proton source with a highly integrated, image-based workflow and robotic patient positioning, making proton therapy a practical clinical reality.
Similar to traditional radiation therapy systems in terms of footprint, workflow, and throughput, the MEVION S250 will easily integrate within existing radiation therapy departments to deliver innovative cancer care in a very conventional way. "Barnes Jewish Hospital prides itself in providing the most advanced technologies to its patients. We are delighted to add this latest development in radiation therapy to our cancer-fighting arsenal", says Jeff Bradley, MD, director of the S. Lee Kling Center for Proton Therapy at Siteman Cancer Center.